LIDODERM Lidocaine patch (lidocaine patch 5%), is a topical therapy that works directly at the site of postherpetic neuralgia (PHN) pain and is backed by more than a decade of use. LIDODERM is the first and only lidocaine-based topical medication approved by the FDA for the treatment of pain associated with PHN, and offers you and your patients a custom fit for PHN pain.

A first-line therapy, alone or with oral analgesics1,2,3

  • Works directly at the site of pain4-6

Proven efficacy in 2 randomized, placebo-controlled clinical trials (N=67)4,7,8

  • In the first study, patients felt significant pain relief at 30 minutes after the first dose vs observation cohort7
  • In the second study, 84% of PHN patients had moderate to complete pain relief at 2 weeks8
  • LIDODERM (lidocaine patch 5%) may take up to 2 weeks to achieve the best outcome4,8

Efficacy of lidocaine patch 5% reaffirmed in a European clinical trial in PHN9

  • Patients remained on lidocaine patch 5% more than twice as long as placebo (median time to exit was 14 days vs 6 days; P=0.0398 per protocol population)
  • Many PHN patients experienced clinically meaningful reductions in painful allodynia at the end of the run-in phase (week 8; n=71)9

Demonstrated favorable safety profile and generally well tolerated4,10,7

  • No serious adverse events in clinical trials7,10
  • Low risk of drug-drug interactions; in clinical trials, patients used concomitant analgesics7,10

Customized application for your patients with PHN pain4

  • A simple application in your office, or at home by your patients
  • Patches can be cut to custom fit the areas of pain

Patients can wear up to 3 patches simultaneously for 12 hours, followed by 12 hours off

Applied to the site of localized pain, the targeted peripheral analgesia of lidocaine is thought to penetrate the dermis, bind to sodium channels, and stabilize neuronal activity, reducing painful impulses and the potential for central sensitization.4, 5, 6
Understand the LIDODERM mechanism of action

Applied in clinical trials, LIDODERM provided significant on-site efficacy (as measured by visual analog, neuropathic, and verbal pain scales).7,10
Read more about LIDODERM efficacy

Applied to intact skin, LIDODERM uses topical technology to deliver analgesia with minimal systemic effect and low risk of serious adverse events.4
Obtain safety data

Applied in the office, LIDODERM allows you and your PHN patients to immediately get "hands-on" with localized pain — targeting right at the site of pathology.4
Learn more about dosing

LIDODERM is recommended for localized pain of PHN by respected third parties, used alone or with oral analgesics.1,2,3,6
Find out more about third party recommendations

Patient Profiles
Read the profiles and hear the stories of real LIDODERM patients
Learn More

Important Safety Information

LIDODERM® (lidocaine patch 5%) is indicated for relief of pain associated with post-herpetic neuralgia. Apply only to intact skin.

LIDODERM is contraindicated in patients with a history of sensitivity to local anesthetics (amide type) or any product component.

Even a used LIDODERM patch contains a large amount of lidocaine (at least 665 mg). The potential exists for a small child or pet to suffer serious adverse effects from chewing or ingesting a new or used LIDODERM patch, although the risk with this formulation has not been evaluated. It is important for patients to store and dispose of LIDODERM out of reach of children, pets, and others.

Excessive dosing, such as applying LIDODERM to larger areas or for longer than the recommended wearing time, could result in increased absorption of lidocaine and high blood concentrations leading to serious adverse effects.

Avoid contact of LIDODERM with the eye. If contact occurs, immediately wash the eye with water or saline and protect it until sensation returns. Avoid the use of external heat sources as this has not been evaluated and may increase plasma lidocaine levels.

Patients with severe hepatic disease are at greater risk of developing toxic blood concentrations of lidocaine, because of their inability to metabolize lidocaine normally. LIDODERM should be used with caution in patients receiving Class I antiarrhythmic drugs (such as tocainide and mexiletine) since the toxic effects are additive and potentially synergistic. LIDODERM should also be used with caution in pregnant (including labor and delivery) or nursing mothers.

Allergic reactions, although rare, can occur.

During or immediately after LIDODERM treatment, the skin at the site of application may develop blisters, bruising, burning sensation, depigmentation, dermatitis, discoloration, edema, erythema, exfoliation, irritation, papules, petechia, pruritus, vesicles, or may be the locus of abnormal sensation. These reactions are generally mild and transient, resolving spontaneously within a few minutes to hours. Other reactions may include dizziness, headache and nausea.

When LIDODERM is used concomitantly with local anesthetic products, the amount absorbed from all formulations must be considered.

Immediately discard used patches or remaining unused portions of cut patches in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.

Before prescribing LIDODERM, please refer to the full Prescribing Information.

References

  1. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237-251.
  2. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289-305.
  3. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63(6):959-965.
  4. LIDODERM Prescribing Information. Chadds Ford, PA: Endo Pharmaceuticals Inc; 2010.
  5. Galer BS. Advances in the treatment of postherpetic neuralgia: the topical lidocaine patch. Today's Therapeutic Trends. 2000;18:1-20.
  6. Argoff CE. Targeted topical peripheral analgesics in the management of pain. Curr Pain Headache Rep. 2003;7(1):34-38.
  7. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65(1):39-44.
  8. Data on file, DOF-LD-02, Endo Pharmaceuticals.
  9. Binder A, Bruxelle J, Rogers P, Hans G, Bösl I, Baron R. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29(6):393-408.
  10. Galer BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain. 1999;80(3):533-538.